ACTH and none was detected in normal children. The specificity of the antisera was directed to the species-specific portion of the porcine ACTH molecule. The presence of circulating antibodies was not associated with resistance to ACTH therapy, allergy or hypersensitivity reactions. There was no correlation between the duration of ACITH therapy, the total dose of ACTH given and the antibody titres obtained. The adrenal responses to pharmacological doses of porcine ACTH or of the pituitary-adrenal axis to intravenous insulin was not related to antibody titre. Thus the development of antibodies to ACTH therapy is variable and without clinical significance. Results of measurements of urinary 17-OGS and plasma free 1l-OHCS in 43 patients with Cushing's syndrome (in 6 due to an adrenal tumour) were presented. Abnormally high values for the midnight plasma free 1 1-OHCS and failure of normal suppression of the urinary 17-OGS with dexamethasone 2 mg/day were found in all the patients. Two patients with pituitary-dependent Cushing's syndrome failed to show the expected fall of urinary 17-OGS with dexamethasone 8 mg/day, and one other patient failed to show a rise of urinary 17-OGS with metyrapone given in a dose of 500 mg three-hourly. The patients included 10 with overt pituitary tumours (on either clinical or radiological grounds) whose preoperative corticosteroid measurements were no different from those of the other patients with pituitary-dependent Cushing's syndrome.
Thirty-six of the patients with test evidence of pituitary-dependence were treated by pituitary implantation of radioactive sources (usually 90Y).
Post-operative assessment showed that some of the patients, who had been judged to have a satis-factory remission, still had abnormally elevated values for the midnight plasma free 11-OHCS and an abnormal diurnal rhythm. In all the patients who sustained a satisfactory remission, the response to metyrapone was blunted with no patient showing a rise of urinary 17-OGS of more than 10 mg/24 hours. By contrast the urinary 17-OGS rose by more than 10 mg/24 hours in the majority of the patients who sustained only a partial remission or who showed no improvement following the operation.
Dr R L Ney, Dr D N Orth and Dr G W Liddle (Vanderbilt University, Nashville, Tennessee, USA)
Evaluation of Pituitary-adrenal Function in Man
Pituitary ACTH secretion in normal man is governed by three known variables: circadian periodicity, feed-back inhibition by cortisol, and stress. Evaluation of the first two of these variables has proved useful in the diagnosis of disorders of pituitary-adrenal function. In Addison's disease, low cortisol production results in high plasma ACTH concentrations; circadian rhythmicity in ACTH levels is maintained. ACTH levels are normal or high in Cushing's disease, but this occurs in spite of increased cortisol production indicating an abnormality in feed-back control of pituitary ACTH; in addition, normal circadian rhythmicity in plasma ACTH is lost. Plasma ACTH concentrations are decreased in Cushing's syndrome due to adrenal neoplasms as a result of feed-back inhibition of pituitary ACTH; circadian rhythmicity in plasma cortisol is not present, but this results from autonomous cortisol production by the tumour. When an adrenal neoplasm is removed, plasma ACTH and cortisol initially are decreased. After several months, plasma ACTH increases to supranormal values and demonstrates circadian rhythmicity. However, adrenal responsiveness is subnormal, resulting in low plasma cortisol values, thus resembling the physiological abnormalities in Addison's disease. After plasma ACTH concentrations have remained elevated for several months, adrenal responsiveness is restored to normal, leading finally to normal plasma cortisol and ACTH levels with normal circadian rhythmicity of each.
